Company news

CanSino Biologics, Inc. news in 2025

CanSino Biologics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Announcement on Voluntary Disclosure of the Initiation of Phase I Clinical Trial of the Adsorbed Acellular Pertussis (Component), Diphtheria and Tetanus, Haemophilus influenzae Type b (Conjugate) – Meningococcal ACYW-135 (Conjugate) Combination Vaccine and the Completion of Enrollment of the First Subject

December 19, 2025

Announcement on Notifying the Creditors of Offsetting Losses with Capital Reserve

November 27, 2025

Announcement on Implementation of Cancellation of Repurchased A-shares

November 26, 2025

Announcement on Voluntary Disclosure of the Initiation of Phase 1 Clinical Trial and Completion of 1st Subject Enrollment for Inhalable Tuberculosis Vaccine (Type 5 Adenovirus Vector) in Indonesia

November 13, 2025

Announcement on Adding Extraordinary Proposal to the 2nd Extraordinary General Meeting in 2025

November 7, 2025

Announcement on Adjusting Matters Related to the 2025 A-share Restricted Stock Incentive Plan

October 27, 2025

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

October 23, 2025

Board of Supervisors' Remarks on Publicity of and Verification Opinions on List of Incentive Objects Initially Granted under 2025 A-share Restricted Stock Incentive Plan

October 17, 2025

-- Announcement on Resolutions of the 9th Meeting of the 3rd Board of Supervisors

September 26, 2025

-- Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Report Performance Briefing

September 2, 2025

-- Announcement on Using Temporarily Idle Raised Funds for Cash Management

August 20, 2025

-- Announcement on Obtaining Notice of Approval for Drug Clinical Trial for Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell)

July 16, 2025

Announcement on the Obtainment of Drug Registration Certificate for 13-valent Pneumococcal Polysaccharide Vaccine (CRM197/Tetanus Toxoid)

June 20, 2025

Announcement on Resolution of the 2024 Annual General Meeting

June 4, 2025

Voluntary Disclosure on the Approval of Clinical Trial for Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) in Indonesia

May 15, 2025

Notice on Convening the 2024 Annual General Meeting

April 29, 2025

Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing

April 22, 2025

Announcement on Renewing Engagement of Accounting Firm

March 25, 2025

Announcement on Preliminary Earnings Estimate for 2024

February 27, 2025

Announcement on Obtaining the Approval Notice for Drug Clinical Trials of Adsorbed Acellular Pertussis (Components), Tetanus, Diphtheria, Haemophilus Influenzae Type b (Conjugate), and Meningococcal Group ACYW135 (Conjugate) Combined Vaccine

February 24, 2025

Announcement on Voluntary Disclosure of Formal Inclusion of the Drug Registration Application for the "Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed" for Infants and Young Children in Priority Review Varieties

February 7, 2025

Announcement on Voluntary Disclosure of Acceptance of Drug Registration Application for Adsorbed Tetanus Vaccine

February 6, 2025

Announcement on Annual Earnings Preannouncement for 2024

January 17, 2025